nach oben

Current Colorectal Cancer Reports

Erschienen in:

09.04.2022 | Systemic Therapies in Colorectal Cancer (SM Kazmi, Section Editor)

Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer

verfasst von: Maria G. Fencer, Catherine H. Davis, Kristen R. Spencer

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Colorectal cancer is the third most common malignancy in the USA with 20% of patients presenting with metastatic disease. While first line agents include cytotoxic chemotherapy regimens, targeted therapies have an increasing role in the management of metastatic colorectal cancer (mCRC). Next Generation Sequencing (NGS) has expanded the ability to identify HER2 variations and is crucial to the next steps in personalized medicine.

Recent Findings

Anti-HER2 therapies provide a promising treatment option for patients who have exhausted traditional regimens including those who have failed prior anti-HER2 therapy. This is in accordance with the 2021 addition of trastuzumab-deruxtecan to the National Comprehensive Cancer Center Guidelines as a subsequent therapy in eligible patients based on the results of the DESTINY-CRC01 trial.

Summary

Various anti-HER2 therapies are approved alone or in combination for patients with mCRC and HER2–amplified tumors. Further investigation into the role of HER2–directed therapy in mutated mCRC is an unmet need, as is the wider use of NGS and ctDNA to explore mechanisms of resistance.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Chen Z, Chen J, Gao Y, Quan M. Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer. Expert Rev Anticancer Ther. 2021;21(10):1097–104. https://doi.org/10.1080/14737140.2021.1944108.CrossRefPubMed

Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. https://doi.org/10.6004/jnccn.2021.0012.CrossRefPubMed

André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343–51. https://doi.org/10.1056/NEJMoa032709.

Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest. 2016;34(2):94–104. https://doi.org/10.3109/07357907.2015.1104689.CrossRefPubMed

Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9.CrossRefPubMed

Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779–86. https://doi.org/10.1200/JCO.2007.11.3357.CrossRefPubMed

Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15(8):819–25. https://doi.org/10.1634/theoncologist.2009-0317.CrossRefPubMedPubMedCentral

Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–401. https://doi.org/10.1001/jama.2017.7105.CrossRefPubMedPubMedCentral

10.

Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. https://doi.org/10.1016/S1470-2045(14)70330-4.CrossRefPubMed

11.

Seufferlein T, Ettrich TJ, Stein A, et al. Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: final results of the multicenter, international PERMAD trial. J Clin Oncol. 2021;39(3_suppl):115–115. https://doi.org/10.1200/JCO.2021.39.3_suppl.115.CrossRef

12.

Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. https://doi.org/10.1016/S0140-6736(12)61900-X.CrossRefPubMed

13.

Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29. https://doi.org/10.1016/S1470-2045(15)70156-7.CrossRefPubMed

14.

Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72. https://doi.org/10.1016/j.ejca.2017.10.009.CrossRefPubMed

15.

Pfeiffer P, Yilmaz M, Moller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412–20. https://doi.org/10.1016/S1470-2045(19)30827-7.CrossRefPubMed

16.

Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98(6):236–8. https://doi.org/10.1136/archdischild-2013-304340.CrossRefPubMedPubMedCentral

17.

Bewicke-Copley F, Arjun Kumar E, Palladino G, Korfi K, Wang J. Applications and analysis of targeted genomic sequencing in cancer studies. Comput Struct Biotechnol J. 2019;17:1348–59. https://doi.org/10.1016/j.csbj.2019.10.004.CrossRefPubMedPubMedCentral

18.

Wei Q, Zhang Y, Gao J, et al. Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clin Colorectal Cancer. 2019;18(3):175–82. https://doi.org/10.1016/j.clcc.2019.05.001.CrossRefPubMed

19.

Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: a 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract. 2021:10781552211005525. https://doi.org/10.1177/10781552211005525.

20.

Fanelli GN, Dal Pozzo CA, Depetris I, et al. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. https://doi.org/10.1186/s12935-020-1117-2.CrossRefPubMedPubMedCentral

21.

Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol. 2020;13:1756284820917527. https://doi.org/10.1177/1756284820917527.CrossRefPubMedPubMedCentral

22.

Shiu K-K, Andre T, Kim TW, et al. KEYNOTE-177: phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol. 2021;39(3_suppl):6–6. https://doi.org/10.1200/JCO.2021.39.3_suppl.6.CrossRef

23.

Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer. Int J Mol Sci. 2021;22(13):6813. https://doi.org/10.3390/ijms22136813. CrossRefPubMedPubMedCentral

24.

Bitar L, Zouein J, Haddad FG, Eid R, Kourie HR. HER2 in metastatic colorectal cancer: a new to target to remember. Biomark Med. 2021;15(2):133–6. https://doi.org/10.2217/bmm-2020-0491.CrossRefPubMed

25.

Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30. https://doi.org/10.1016/S1470-2045(18)30904-5.CrossRefPubMedPubMedCentral

26.

• Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73. https://doi.org/10.1002/cncr.31125. Lays out the differences between HER2 amplification and HER2 mutations and demonstrates the incidence of their association with other common alterations such as TP53, KRAS, and MSI.CrossRefPubMed

27.

Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279. https://doi.org/10.1136/esmoopen-2017-000279.CrossRefPubMedPubMedCentral

28.

Yagisawa M, Sawada K, Nakamura Y, et al. Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20(2):113-120 e1. https://doi.org/10.1016/j.clcc.2020.11.002.CrossRefPubMed

29.

Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25(10):3046–53. https://doi.org/10.1158/1078-0432.CCR-18-3389.CrossRefPubMed

30.

Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://doi.org/10.1016/S1470-2045(16)00150-9.CrossRefPubMed

31.

Ni S, Peng J, Huang D, et al. HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): a large-scale retrospective study in Chinese population. Ann Oncol. 2017;28:v191. https://doi.org/10.1093/annonc/mdx393.089.CrossRef

32.

Wu SW, Ma CC, Li WH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol. 2015;10:144. https://doi.org/10.1186/s13000-015-0380-3.CrossRefPubMedPubMedCentral

33.

Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–70. https://doi.org/10.1002/path.4679.CrossRefPubMedPubMedCentral

34.

Huang W, Chen Y, Chang W, et al. HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. J Cancer Res Clin Oncol. 2021. https://doi.org/10.1007/s00432-021-03655-x.CrossRefPubMedPubMedCentral

35.

•• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–89. https://doi.org/10.1016/S1470-2045(21)00086-3. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines.CrossRefPubMed

36.

Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;3:1–13. https://doi.org/10.1200/po.18.00226.CrossRefPubMed

37.

Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers 2018;10(10):342. https://doi.org/10.3390/cancers10100342.

38.

Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19(4):256-262 e2. https://doi.org/10.1016/j.clcc.2020.06.009.CrossRefPubMed

39.

Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020;5(5):e000911. https://doi.org/10.1136/esmoopen-2020-000911.CrossRefPubMedPubMedCentral

40.

Siena S, Elez E, Peeters M, et al. PD-1 MOUNTAINEER: open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). Ann Oncol. 2021;32:S199. https://doi.org/10.1016/j.annonc.2021.05.019.CrossRef

41.

Shah M, Wedam S, Cheng J, et al. FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27(5):1220–6. https://doi.org/10.1158/1078-0432.CCR-20-2701.CrossRefPubMed

42.

Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. https://doi.org/10.1056/NEJMoa1914609.CrossRefPubMed

43.

Gupta R, Garrett-Mayer E, Halabi S, et al. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: results from the TAPUR Study. J Clin Oncol. 2020;38(4_suppl):132–132. https://doi.org/10.1200/JCO.2020.38.4_suppl.132.CrossRef

44.

• Okamoto W, Nakamura Y, Kato T, et al. Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). J Clin Oncol. 2021;39(15_suppl):3555–3555. https://doi.org/10.1200/JCO.2021.39.15_suppl.3555. Most recent updates published regarding the TRIUMPH trial which helped demonstrate the efficacy of ctDNA when compared the standard of care (tissue biopsy) at identifying HER2 status and subsequent treatment response.CrossRef

45.

• Yoshino T, Bartolomeo MD, Raghav KPS, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2021;39(15_suppl):3505–3505. https://doi.org/10.1200/JCO.2021.39.15_suppl.3505. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines.CrossRef

46.

Jacobs SA, Lee JJ, George TJ, et al. NSABP FC-11: a phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with “quadruple wild-type (WT)” (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status—amplified (amp), non-amplified (non-amp), WT, or mutated (mt). J Clin Oncol. 2019;37(4_suppl):TPS716–TPS716. https://doi.org/10.1200/JCO.2019.37.4_suppl.TPS716.CrossRef

47.

Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2015;7:147–62. https://doi.org/10.2147/BCTT.S54414.CrossRef

Titel: Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer
verfasst von: Maria G. Fencer
Catherine H. Davis
Kristen R. Spencer
Publikationsdatum: 09.04.2022
Verlag: Springer US
Erschienen in: Current Colorectal Cancer Reports / Ausgabe 2/2022
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-022-00475-0

Springer Medizin

Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer